In the race to forge the next Keytruda from PD-(L)1xVEGF bispecific antibodies, Pfizer and the BioNTech-Bristol Myers Squibb alliance are split on how to position overall survival—the gold-standard ...
The U.S. Food and Drug Administration (FDA) is unlikely to renew the authorization granted to use Pfizer (NYSE:PFE) and BioNTech’s (BNTX) COVID-19 vaccine in young children this fall, The Guardian ...
The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...
3don MSNOpinion
Opportunities in the oncology market: Positioning for the next billion-dollar catalyst with BioNTech, Vidac Pharma, and Pfizer
Large Pipeline The first-quarter figures were sobering. BioNTech generated revenue of just EUR 118.1 million, a decline of ...
Due to Pfizer’s underperformance relative to its peers over the past year, Wall Street analysts remain cautious about the ...
The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...
Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results